Enamino-oxindole HIV protease inhibitors.
Eissenstat, M., Guerassina, T., Gulnik, S., Afonina, E., Silva, A.M., Ludtke, D., Yokoe, H., Yu, B., Erickson, J.(2012) Bioorg Med Chem Lett 22: 5078-5083
- PubMed: 22749283
- DOI: https://doi.org/10.1016/j.bmcl.2012.05.120
- Primary Citation of Related Structures:
4FE6 - PubMed Abstract:
We have designed and synthesized a series of HIV protease inhibitors (PIs) with enamino-oxindole substituents optimized to interact with the S2' subsite of the HIV protease binding pocket. Several of these inhibitors have sub-nanomolar K(i) and antiviral IC(50) in the low nM range against WT HIV and against a panel of multi-drug resistant (MDR) strains.
Organizational Affiliation:
Sequoia Pharmaceuticals, Inc., Gaithersburg, MD 10878, USA. eissenst@comcast.net